Literature DB >> 27716750

Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.

M Gemenetzi1, A J Lotery2,3, P J Patel1.   

Abstract

Anti-vascular endothelial growth factor (VEGF) intravitreal agents are the only successful treatment for wet age-related macular degeneration (AMD). However, there are emerging signals that anti-VEGF treatment can potentially increase development of geographic atrophy (GA). Histopathologic, animal, and clinical studies support this hypothesis although direct proof of a relationship between GA and use of anti-VEGF agents in neovascular AMD is not yet established. This review presents current evidence supporting an association between anti-VEGF therapy and progression of geographic atrophy. The need of exploring alternative methods of treating AMD is indirectly but clearly emphasized.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27716750      PMCID： PMC5233933          DOI： 10.1038/eye.2016.208

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


  54 in total

1.  HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Michael A Singer; Carl C Awh; SriniVas Sadda; William R Freeman; Andrew N Antoszyk; Pamela Wong; Lisa Tuomi
Journal:  Ophthalmology       Date:  2012-02-04       Impact factor: 12.079

2.  An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris.

Authors:  Magali Saint-Geniez; Tomoki Kurihara; Eiichi Sekiyama; Angel E Maldonado; Patricia A D'Amore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

3.  Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.

Authors:  Marcela Marsiglia; Sucharita Boddu; Christine Y Chen; Jesse J Jung; Sarah Mrejen; Roberto Gallego-Pinazo; K Bailey Freund
Journal:  Retina       Date:  2015-05       Impact factor: 4.256

4.  Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1997-06

5.  Eccentric visual acuity in patients with macular disease.

Authors:  M J Harris; D Robins; J M Dieter; S L Fine; D L Guyton
Journal:  Ophthalmology       Date:  1985-11       Impact factor: 12.079

6.  Atrophic macular degeneration. Rate of spread of geographic atrophy and visual loss.

Authors:  H Schatz; H R McDonald
Journal:  Ophthalmology       Date:  1989-10       Impact factor: 12.079

Review 7.  Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex.

Authors:  Imran Bhutto; Gerard Lutty
Journal:  Mol Aspects Med       Date:  2012-04-21

8.  The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.

Authors: 
Journal:  Ophthalmology       Date:  2014-01-23       Impact factor: 12.079

9.  The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study.

Authors:  Ronald Klein; Stacy M Meuer; Michael D Knudtson; Barbara E K Klein
Journal:  Am J Ophthalmol       Date:  2008-07-30       Impact factor: 5.258

10.  PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Authors:  Nizar Saleh Abdelfattah; Hongyang Zhang; David S Boyer; SriniVas R Sadda
Journal:  Retina       Date:  2016-10       Impact factor: 4.256
View more
  36 in total

1.  Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease.

Authors:  Odunayo O Mugisho; Colin R Green; David M Squirrell; Sarah Bould; Helen V Danesh-Meyer; Jie Zhang; Monica L Acosta; Ilva D Rupenthal
Journal:  J Mol Med (Berl)       Date:  2018-12-08       Impact factor: 4.599

Review 2.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

3.  Potential selection bias in candidates for stereotactic radiotherapy for neovascular AMD.

Authors:  Christoph Ehlken; Daniel Böhringer; Hansjürgen T Agostini; Bastian Grundel; Milena Stech
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-22       Impact factor: 3.117

4.  ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.

Authors:  Alicia Valverde-Megías; Silvia Veganzones-de-Castro; Juan Donate-López; Maria Luisa Maestro-de-Las-Casas; Alicia Megías-Fresno; Julián García-Feijoo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-25       Impact factor: 3.117

Review 5.  Clinical pharmacology of intravitreal anti-VEGF drugs.

Authors:  Stefano Fogli; Marzia Del Re; Eleonora Rofi; Chiara Posarelli; Michele Figus; Romano Danesi
Journal:  Eye (Lond)       Date:  2018-02-05       Impact factor: 3.775

6.  miR-30a-5p inhibition promotes interaction of Fas+ endothelial cells and FasL+ microglia to decrease pathological neovascularization and promote physiological angiogenesis.

Authors:  Salome Murinello; Yoshihiko Usui; Susumu Sakimoto; Maki Kitano; Edith Aguilar; H Maura Friedlander; Amelia Schricker; Carli Wittgrove; Yoshihiro Wakabayashi; Michael I Dorrell; Peter D Westenskow; Martin Friedlander
Journal:  Glia       Date:  2018-11-28       Impact factor: 7.452

7.  Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.

Authors:  Thomas A Vo; Sina Abedi; Kevin Schneider; Marilyn Chwa; M Cristina Kenney
Journal:  Exp Eye Res       Date:  2018-07-30       Impact factor: 3.467

8.  Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.

Authors:  Ebenezer Daniel; Maureen G Maguire; Juan E Grunwald; Cynthia A Toth; Glenn J Jaffe; Daniel F Martin; Gui-Shuang Ying
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

9.  Nonexudative Macular Neovascularization - A Systematic Review of Prevalence, Natural History, and Recent Insights from OCT Angiography.

Authors:  Rita Laiginhas; Jin Yang; Philip J Rosenfeld; Manuel Falcão
Journal:  Ophthalmol Retina       Date:  2020-03-13

10.  The effects of anti-VEGF and kinin B1 receptor blockade on retinal inflammation in laser-induced choroidal neovascularization.

Authors:  Soumaya Hachana; Olivier Fontaine; Przemyslaw Sapieha; Mark Lesk; Réjean Couture; Elvire Vaucher
Journal:  Br J Pharmacol       Date:  2020-02-04       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.